6 years ago

PolyProx Therapeutics Secures £3.4 Million Seed Funding for Cancer Drug Development

  • PolyProx Therapeutics, a Cambridge, UK-based biotechnology company focused on developing cancer treatments, has raised £3.4 million in seed funding

  • The round was co-led by Cambridge Innovation Capital plc (CIC), RT Capital and Cambridge Enterprise

  • The company plans to use the funds to expand research operations and validate its technology across a range of tumor targets over the next two years

  • PolyProx Therapeutics is advancing a new class of drugs, called Polyproxin™ molecules, that target tumor cells and trigger natural degradation to arrest growth.

      • ProblemHealthcare

      "Current cancer treatments often have severe side effects and can be ineffective for many patients, leaving a huge unmet need for new treatments."

      Solution

      "PolyProx Therapeutics is developing a new class of drugs called Polyproxin™ molecules that target tumor cells and trigger their natural degradation machinery to stop tumor growth."

      Covered on